Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Naughton

Showing results (31-40 of 42) with videos related to

Pageof 5
Sort By:
International Journal of Radiation Oncology, Biology, Physics|March 11, 2014
Five fractions of radiation therapy followed by 4 cycles of FOLFOX chemotherapy as preoperative treatment for rectal cancerRobert J Myerson, Benjamin Tan, Steven Hunt, et al.
Cancer Chemotherapy and Pharmacology|June 12, 2014
A phase I study of pegylated liposomal doxorubicin and temsirolimus in patients with refractory solid malignanciesAndrea Wang-Gillam, Nilay Thakkar, A Craig Lockhart, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 14, 2015
A Phase I Trial of BKM120 (Buparlisib) in Combination with Fulvestrant in Postmenopausal Women with Estrogen Receptor-Positive Metastatic Breast CancerCynthia X Ma, Jingqin Luo, Michael Naughton, et al.
Clinical Pharmacology and Therapeutics|September 28, 2018
A Pharmacogenetic Prediction Model of Progression-Free Survival in Breast Cancer using Genome-Wide Genotyping Data from CALGB 40502 (Alliance)Sara R Rashkin, Katherina C Chua, Carol Ho, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 3, 2010
Breast cancer adjuvant chemotherapy decisions in older women: the role of patient preference and interactions with physiciansJeanne S Mandelblatt, Vanessa B Sheppard, Arti Hurria, et al.
The Lancet. Oncology|April 6, 2010
Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trialRebecca Aft, Michael Naughton, Kathryn Trinkaus, et al.
NPJ Breast Cancer|July 20, 2017
Randomized phase II trial of fulvestrant alone or in combination with bortezomib in hormone receptor-positive metastatic breast cancer resistant to aromatase inhibitors: a New York Cancer Consortium trialKerin Adelson, Bhuvaneswari Ramaswamy, Joseph A Sparano, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 7, 2017
Neratinib Efficacy and Circulating Tumor DNA Detection of <i>HER2</i> Mutations in <i>HER2</i> Nonamplified Metastatic Breast CancerCynthia X Ma, Ron Bose, Feng Gao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 7, 2017
A Phase II Trial of Neoadjuvant MK-2206, an AKT Inhibitor, with Anastrozole in Clinical Stage II or III <i>PIK3CA</i>-Mutant ER-Positive and HER2-Negative Breast CancerCynthia X Ma, Vera Suman, Matthew P Goetz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 9, 2017
NeoPalAna: Neoadjuvant Palbociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, and Anastrozole for Clinical Stage 2 or 3 Estrogen Receptor-Positive Breast CancerCynthia X Ma, Feng Gao, Jingqin Luo, et al.
Pageof 5

Showing results (31-40 of 42) with videos related to

Sort By:
Pageof 5
International Journal of Radiation Oncology, Biology, Physics|March 11, 2014
Five fractions of radiation therapy followed by 4 cycles of FOLFOX chemotherapy as preoperative treatment for rectal cancerRobert J Myerson, Benjamin Tan, Steven Hunt, et al.
Cancer Chemotherapy and Pharmacology|June 12, 2014
A phase I study of pegylated liposomal doxorubicin and temsirolimus in patients with refractory solid malignanciesAndrea Wang-Gillam, Nilay Thakkar, A Craig Lockhart, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 14, 2015
A Phase I Trial of BKM120 (Buparlisib) in Combination with Fulvestrant in Postmenopausal Women with Estrogen Receptor-Positive Metastatic Breast CancerCynthia X Ma, Jingqin Luo, Michael Naughton, et al.
Clinical Pharmacology and Therapeutics|September 28, 2018
A Pharmacogenetic Prediction Model of Progression-Free Survival in Breast Cancer using Genome-Wide Genotyping Data from CALGB 40502 (Alliance)Sara R Rashkin, Katherina C Chua, Carol Ho, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 3, 2010
Breast cancer adjuvant chemotherapy decisions in older women: the role of patient preference and interactions with physiciansJeanne S Mandelblatt, Vanessa B Sheppard, Arti Hurria, et al.
The Lancet. Oncology|April 6, 2010
Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trialRebecca Aft, Michael Naughton, Kathryn Trinkaus, et al.
NPJ Breast Cancer|July 20, 2017
Randomized phase II trial of fulvestrant alone or in combination with bortezomib in hormone receptor-positive metastatic breast cancer resistant to aromatase inhibitors: a New York Cancer Consortium trialKerin Adelson, Bhuvaneswari Ramaswamy, Joseph A Sparano, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 7, 2017
Neratinib Efficacy and Circulating Tumor DNA Detection of <i>HER2</i> Mutations in <i>HER2</i> Nonamplified Metastatic Breast CancerCynthia X Ma, Ron Bose, Feng Gao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 7, 2017
A Phase II Trial of Neoadjuvant MK-2206, an AKT Inhibitor, with Anastrozole in Clinical Stage II or III <i>PIK3CA</i>-Mutant ER-Positive and HER2-Negative Breast CancerCynthia X Ma, Vera Suman, Matthew P Goetz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 9, 2017
NeoPalAna: Neoadjuvant Palbociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, and Anastrozole for Clinical Stage 2 or 3 Estrogen Receptor-Positive Breast CancerCynthia X Ma, Feng Gao, Jingqin Luo, et al.
Pageof 5